The additional $50 million will go towards venture capital firms that specialize in near- and long-term healthcare solutions for patients in low- and middle-income countries
Lebrikizumab is an investigational high-affinity and potent IL-13 inhibitor being studied in adult and adolescent patients
Cipla has recently signed an agreement to make and market the diabetes therapy Galvus and its combination brands in India from 01 January 2026.
Abbas will closely partner with CBC's business teams to identify, assess, and pursue investment opportunities and strategic acquisitions
Julie is recognized as a highly engaging multi-cultural leader skilled in fluidly partnering with cross-functional teams to deliver results.
The Innovation Explorer database of GlobalData’s Disruptor Intelligence Center highlights the key company collaborations in pharma to advance AI-powered drug repurposing techniques.
The supplemental New Drug Application is based on results from the landmark EMPA-KIDNEY phase III trial
To create leading company developing medicines targeting metalloenzymes
Allam was serving recently as the CEO at Public Investment Fund
Subscribe To Our Newsletter & Stay Updated
